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Abstract
Background: Multimorbid patients frequently receive complex medication regimens and are at higher risk for
adverse drug reactions and hospitalisations. Managing patients with polypharmacy is demanding, because it
requires coordination of multiple prescribers and intensive monitoring. Three evidence-based recommendations
addressing polypharmacy in primary care are structured medication counselling, use of medication lists and
medication reviews to avoid potentially inappropriate medication (PIM). Although promising to improve patient
outcomes, these recommendations are not well implemented in German routine care. Implementation of guidelines
is often hindered by specific “determinants of change”. “Tailored” interventions are designed to specifically address
previously identified determinants. This study examines a tailored intervention tto implement the aforementioned
recommendations into German primary care practices. This study is part of the European Tailored Interventions for
Chronic Diseases project, which aims at contributing knowledge about the methods used for tailoring.
Methods/Design: The study is designed as a cluster randomized controlled trial with primary care practices of general
practitioners (GPs) who are organized in quality circles. Quality circles will be the unit of randomization with a 1:1 ratio.
Follow-up time is 6 months. GPs and healthcare assistants in the intervention group will receive training on medication
management. Each GP will create a tailored concept of how to implement the three recommendations into his/her
practice. Evidence-based checklists for medication counselling and medication reviews will be provided for physicians.
A tablet PC with an interactive educational tool and information leaflets will be provided for use by patients to inform
about the necessity of continuous medication management. Control practices will not receive special training and will
provide care as usual. Primary outcome is the degree of implementation of the three recommendations, which will be
measured using a prespecified set of indicators. Additionally, the PIM prescription rate, patient activation, patients’
beliefs about medicine, medication adherence and patients’ social support will be measured.
Discussion: This study will contribute knowledge about the feasibility of implementing recommendations for
managing patients with polypharmacy in primary care practices. Additionally, this study will contribute knowledge
about methods for tailoring of implementation interventions.
Trial registration: Clinicaltrials.gov ISRCTN34664024
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Background
An increasing number of patients have multiple chronic
conditions [1]. Multimorbidity is associated with an in-
creased likelihood of complex medication regimens often
consisting of five or more different drugs, commonly de-
fined as polypharmacy [2]. With administration of increa-
sing numbers of drugs, the risk of adverse drug reactions
(ADRs) increases substantially [3] thereby causing poten-
tially avoidable hospital admissions [4] and preventable
deaths [5]. Managing multimorbid patients with polyphar-
macy is particularly demanding in primary care practices
(PCPs), as it requires coordination of multiple prescribers,
profound pharmacological knowledge and intense moni-
toring of patients.
Recommendations for patients with polypharmacy
An increasing body of literature has been published re-
garding strategies to address polypharmacy in multimor-
bid patients [6]. For the Polypharmacy in Multimorbid
Patients (PomP) study, three core recommendations de-
rived from the literature have been identified. German
guidelines for polypharmacy in primary care, which were
published after we made this selection, refer to these
recommendations [7].
(1)Recommendation 1/structured medication
counseling (SMC): all patients with polypharmacy
and additional risk factors for medication problems
should receive SMC at least once per year. In
addition to medication-related information, SMC
comprises a complete inventory of the medications
actually taken (a so-called “brown bag review”) and
assessment of patient adherence and possible
application problems. A separate appointment
should be planned for SMC [8].
(2)Recommendation 2/consequent use of medication
lists: All patients with polypharmacy should take
along an updated, complete (that is, containing all
necessary information) and comprehensible
medication list [7,9].
(3)Recommendation 3/medication reviews to reduce
potentially inappropriate medication (PIM): The
appropriateness of a medication can be judged by using
explicit criteria (usually drug-to-avoid lists) and implicit
criteria (usually checklists). Since 2010, the PRISCUS
list has been available in Germany. It lists 82 drugs as
potentially inappropriate for use in older patients [10].
The Medication Appropriateness Index (MAI) is a tool
to systematically check individual medication regimens
to ensure that they meet criteria such as indication,
dosage, interactions and applications [11]. It is
recommended that physicians, with the aid of such
tools, regularly review the medication regimens of
patients with polypharmacy [7].
Current routine care
Implementation of these recommendations would likely
improve medication management and the health status
of multimorbid patients with polypharmacy [7]. To date,
however, these recommendations have not been imple-
mented well in German routine care.
Deficiencies concerning communication between physi-
cians and patients about their medicine are well-known,
both at discharge and in ambulatory care [12-14]. Infor-
mation about medication is usually given only at the time
of first prescription, and monitoring of efficacy and ADRs
is often insufficient [14]. Patients are dissatisfied with the
information provided about possible side effects and feel
that there is little chance to discuss their questions and
concerns during the consultation [15]. There is evidence
that SMC may increase patient satisfaction [16], improve
adherence and reduce ADRs and hospitalizations [17].
Several independent studies have shown that there are
discrepancies between medication records and actual
medication intake in about 75% of cases [18-20] and that
25% of those discrepancies are potentially harmful [21].
In a recent study, it was reported that 40% of primary
care patients in Germany reported taking a mean of two
drugs of which their general practitioners (GPs) were
unaware [22]. Organizational issues (for example, medi-
cation records not being updated) were the most fre-
quent cause of differences between medication records
and actual medication intake.
An analysis based on the PRISCUS list showed that
25% of the elderly received at least one PIM prescription
in 2010 [23]. Medication errors, defined according to
the criteria of the MAI, are frequent. An Austrian study
examining the medication regimens of 169 patients with
polypharmacy in 22 general practices found that, on
average, 2.7 medications per patient were not indicated
and that 93.5% had taken at least one non-evidence-
based medication [24].
Healthcare system
The challenge of managing patients with polypharmacy
is particularly relevant for countries without an estab-
lished gatekeeping system. Germany has a strong ambu-
latory specialist care system in addition to primary care.
Patients have free choice of doctors and do not have to
be registered at any PCP. Therefore, different care pro-
viders are able to alter medication regimens without
communication with the GP.
In an attempt to strengthen the coordinating role of
GPs, some German health insurance policies offer GP-
centred care contracts (Hausarztzentrierte Versorgung,
or HzV). Patients who are voluntarily enrolled in an
HzV contract agree to get a referral from a GP before
they contact a specialist. Specialists who voluntarily par-
ticipate in HzV are obliged to send a report to the GP
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after each patient contact. GPs participating in the HzV
care contract of one German health insurance in one
federal state in Germany (“HzV AOK Baden-Württemberg”
care contract) [25] are additionally obliged to participate
regularly in quality circles (QCs) [26], which comprise
small-group meetings of GPs from one geographical
region and written feedback on their individual practice
patterns. Currently, there are 309 QCs in the German
federal state Baden-Württemberg, each comprising on
average 10.9 GPs (±5.6).
Tailored interventions
Implementation of evidence-based practice in healthcare
is often hindered by specific barriers and promoted by
enablers, also referred to as “determinants of change”.
Interventions designed to address previously identified
determinants are often referred to as “tailored interven-
tions” [27]. This study is part of the tailored interven-
tions for chronic diseases (TICD) project, which aims to
contribute knowledge to gain a better understanding of
methods used to tailor implementation interventions in
chronic illness care [28]. On the basis of prior work of
the TICD project, the aim of the PomP study is to assess
the effectiveness of a tailored implementation interven-
tion for polypharmacy in multimorbid patients.
Methods
Trial design
The intent of the PomP study investigators is to im-
prove the implementation of the aforementioned core
recommendations. The aim is to assess the effectiveness
of a tailored implementation intervention compared to
usual care in professional practice. The study design is a
two-armed cluster randomized controlled trial with
QCs of PCPs with a 1:1 ratio of units of randomization
(see Figure 1). Follow-up time is 6 months.
Study setting and participants
PCPs enrolled in the “HzVAoK Baden-Württemberg” care
contract and organized in QCs [29] with thrice-monthly
meetings will be recruited into the study as participants.
Each PCP will include 20 to 25 patients according to the
following eligibility criteria.
The eligibility criterion for QCs is the participation of at
least 75% of the PCPs of one QC. For PCPs, the criteria
for inclusion are enrolment in the HzV AOK Baden-
Württemberg care contract and continuous attendance at
specific QC meetings every 3 months during the previous
12 months. The eligibility criteria for patients are age
older than 64 years, enrolment in the HzV AOK Baden-
Württemberg care contract, prescriptions for more than
four different drugs in at least one quarter of the year,
diagnosis of at least three chronic conditions based on a
previously published diagnosis list [30] and high risk of
medication problems (according to the personal assess-
ment of the GP, such as nonadherence or hospitalisation
due to medication-related events).
Exclusion criteria are PCPs that have participated in
another study focused on multimorbidity or polyphar-


















Figure 1 Trial design of the Polypharmacy in Multimorbid Patients study. Primary care practices (PCPs) organised in quality circles (QCs) are
randomized by QC level. QCs are educational meetings of PCPs from one geographic area.
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problems (as assessed by GPs via chart review) and cog-
nitive or clinical status of patients that hinders active
participation in the study.
Intervention study group
The PomP study tailored intervention was developed on
the basis of previously identified determinants and stra-
tegies. The result of this previous work was a standardised
list of determinants for implementing into practice the
three core recommendations (SMC, use of medication
lists and medication reviews to reduce PIM), as well as a
set of strategies addressing these determinants. An imple-
mentation intervention has been designed on the basis of
this prior work. Each strategy within the implementation
intervention addresses one or more specific determinants.
Figure 2 specifies which determinant is meant to be ad-
dressed by each strategy. The strategies used in the imple-
mentation interventions are outlined in the following
subsections.
Workshops
GPs and healthcare assistants (HCAs) will receive training
in four main areas: (1) medication counselling; (2) medica-
tion management, including the use of medication lists;
(3) pharmacological issues, including PIMs; and (4) organ-
isational study issues, such as documentation, use of tablet
PCs and creation of practice-based pathways. A half-day
training session will be organised by the study team for all
PCPs in the intervention group. At least one GP and one
HCA from each PCP must be present. The aim of the
training sessions is to increase expert knowledge of medi-
cation management.
Individual practice concepts
Each PCP team will create an individual concept which
describes how they plan to implement the recommenda-
tions into their practice. The aim of individual practice
concepts is to enhance awareness of the processes and
possible performance gaps in the individual practice and
to optimise management processes of the PCP by clearly
defining responsibilities and tasks and by designing tai-
lored strategies for each PCP.
Presentation of individual practice concepts at quality circle
meetings
Each QC is obliged to organise one meeting in addition to
their regular agenda, during which each practice team will
present its individual implementation concept. The aim of
this meeting is to increase the likelihood that practice con-
cepts will be elaborated and to set the stage for the exchange
of ideas for individual solutions among the QC participants.
Checklist for SMC and medication reviews
A checklist for SMC and medication reviews [8] will be
handed out to all PCPs of the intervention group and
should be used to document each SMC review and each
medication review. The checklist for medication reviews
will be based on the components of the MAI [11]. The
aim of the checklist is to structure and thus facilitate the































Definition of target group
Feasibility of checklists
Figure 2 Logic model of the tailored implementation intervention in the Polypharmacy in Multimorbid Patients study. QC, quality circle;
SMC, structured medication counselling.
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Template for medication lists
A template for medication lists will be given to each PCP
as an adaptable text file [9]. Practice teams are supposed
to make sure that the medication lists they use by default
contain the information specified in the template.
Tablet PCs for patients
A tablet PC with an interactive educational tool for the
three core recommendations for patients will be provided
(one tablet PC per PCP). The tool will be available in
German, English and Turkish to reach a broader spectrum
of patients, including non-German-speaking patients. All
patients in the target group, as defined by the previously
created patient register, should complete the educational
tool at least once. The aim of the tool is to increase
patients’ interest in and awareness of medication-related
topics and thus introduce a behaviour change that results
in a higher proportion of patients carrying a medication
list with them and reporting medication changes and
problems proactively to GPs. Difficulties in comprehen-
sion due to language barriers will be reduced.
Campaign
Posters and flyers for patients with information about
the three core recommendations will be provided. Flyers
should be placed in the PCP waiting room and handed
out to the patients in the target group. Posters should be
hung on the walls in the PCP. The aim of the campaign
is identical to that of the tablet PC; however, all patients
visiting the practices of the intervention group will be
exposed to the campaign, whereas the tablet PC tool is
to be used only by a sample of patients.
Determinants identified and prioritised, but not ad-
dressed by this intervention are cognitively impaired
patients, lack of resources (time, financial compen-
sation), multiple information sources, information ex-
change at interfaces, compatibility of practice software,
data security, rebate contracts, alternatives to PIM, dis-
charge medication, geriatric/pharmacological consulta-
tions, easy access to PIM and entering medication data
into software programs.
Usual care study group
PCPs in the usual care group will participate in thrice-
monthly QCs thematically different from those in the
intervention group. They will not receive special training
in medication management. These PCPs will continue to
deliver care as usual within the framework of the GP-
centred care contract. GPs in the control group will be
informed about the three recommendations by receiving
the information leaflet explaining the PomP study.
Primary outcome
The primary outcome will be the degree of implementa-
tion of the three recommendations measured at the pa-
tient level, that is the effectiveness of the implementation
program on PCP performance. This will be assessed using
a set of indicators. The degree of implementation will be
expressed by the number of indicators fulfilled per patient
included in the study (see Table 1).
Secondary outcomes
All patients entering the PCP on two randomly selected
days will be asked whether they take permanent medica-
tion, whether they carry a medication list with them and
whether they have received a medication list from their
GP. Furthermore, the PIM prescription rate (based on
the PRISCUS list [10]) per patient will be measured
using insurance claims data.
A number of questionnaires will be used to assess
medication-related outcomes in detail on a per-patient
level: the Patient Activation Measure [31], the Medica-
tion Adherence Report Scale [32], the Beliefs About
Medicine Questionnaire [33] and the Social Support
Questionnaire [34].
On the basis of previous evidence, it is assumed
that implementation of the recommendations will lead
to improved health outcomes. However, clinical out-
comes will not be determined in this study. In order
to describe the sample, and in the context of a com-
prehensive process evaluation, we will collect socio-
demographic data about the selected and unselected
participants.
Table 1 Indicators of successful implementation of the
core recommendationsa
Indicator (per included patient) Yes/No
Recommendation 1: Structured medication counselling
SMC was performed at least once according
to the checklist
Y/N
BBR has been performed at least once Y/N
Recommendation 2: Use of medication lists
Patient’s medication list is concordant with
physician’s medication list
Y/N
Medication list is consistent with template Y/N
Patients carry medication list with them Y/N
Date on medication list not older than
6 months
Y/N
Recommendation 3: Medication checks to reduce PIM
Medication review was performed according
the checklist/MAI score at least onceb
Y/N
aBBR, brown bag review; MAI, Medication Appropriateness Index; PIM,
potentially inappropriate medication; SMC, structured medication counselling.
bSamsa et al. [11].
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Sample size
We will include two QCs (about twenty practices) in the
intervention group and two QCs (about twenty practices)
in the control group. Based on data derived from PIM
prescriptions at the patient, practice and QC levels, an
intracluster coefficient (ICC) of 0.02 at the practice level
and an ICC of 0.0008 at the QC level could be estimated
based on assumptions regarding the effect of variance
inflation factors from two-level trials [35]. Assuming 20
practices and 3,400 patients per group (PIMs will be
assessed for all patients of a practice, regardless of whether
they are specifically targeted by the program), a reduction
of PIM prescriptions with a standardised effect size of 0.6
could be detected with Crohnbach’s α error of 5% and a β
error of 20%. Assuming that PCP performance in the
other domains (SMC and medication lists) will not be less
than performance on PIM prescriptions, an overall effect
size of 0.6 is a reasonable expectation for the primary
outcome.
Statistical methods
Data will be analysed in accordance with the Consolidated
Standards of Reporting Trials (CONSORT) statement and
its extension for cluster randomized trials [36]. A fully
specified statistical analysis plan will be provided prior to
the beginning of statistical analyses.
Intention-to-treat as well as per-protocol analyses will
be performed. Descriptive statistics will be used to sum-
marise characteristics of both PCPs and patients by using
means and 95% confidence intervals for continuous data
and absolute numbers for categorical or nominal data. A
multilevel modelling approach [37] will be applied to
evaluate differences between the intervention group and
the control group for all outcomes. This approach will be
used to account for the hierarchical structure of the data
(that is, patients nested within practices nested within
QCs). The effect of the intervention on the primary out-
come will be tested at the two-sided significance level of
5%. The result will be presented as the difference between
group means with the corresponding 95% confidence
interval after adjustment for baseline characteristics. In-
terim analyses are not planned. Statistical analyses will be
carried out using R version 2.15.3 or higher software [38].
Recruitment
Recruitment of primary care practices and quality circles
For recruitment of PCPs, the moderators of all QCs in
one large geographic region in Baden-Württemberg
(about 11 million inhabitants) will be addressed and in-
formed about the study. Moderators will inform GPs
participating in the QCs and ask for the GPs’ written in-
formed consent to participate. At least 75% of the PCPs
of one QC must participate in order to be included with
the QCs in the study.
Recruitment of patients
Each GP will receive a deidentified list of patients assigned
to the “HzV AOK Baden-Württemberg” care contract who
have received repeated prescriptions for more than four
drugs in the previous year, based on insurance claims data.
For each patient, information regarding age, gender and
the prescribed medication will be provided. GPs will create
a patient register by selecting 25 patients from this list who
are able to participate in the study and have, from the GPs’
point of view, a high risk for medication problems. GPs
will ask patients to give their written informed consent
to participate.
Incentives
Each PCP in the intervention and control groups will re-
ceive a tablet PC at the beginning of the study as an
incentive to participate. PCPs in the intervention group
will additionally receive a financial allowance if they
complete the study.
Randomization
QCs will be randomly allocated to the intervention or
control group at a ratio of 1:1. We will perform ran-
domization with numbers generated using R software
[38]. Randomization will be performed by a research as-
sistant who will not otherwise be involved in the project.
After this step, PCPs will be informed about their assign-
ment by an official letter sent from the study coordi-
nating centre. All participants will be able to decline to
participate once they know to which group they have
been assigned. Allocation will be concealed until base-
line data collection is finished in each centre.
Blinding
Owing to the nature of the intervention, blinding of the
participants will not be possible for this intervention
(PCPs). Analysing researchers will be blinded to alloca-
tion to minimize bias.
Data collection methods
Trained study nurses will visit the PCPs twice: at T0 and
T1. During the PCP visits, all patients entering the PCP
will be asked whether they perceive polypharmacy,
whether they carry a medication list with them and
whether they have received a medication list from their
GP. These data will be collected anonymously by using a
tally sheet.
Patient and GP questionnaires will be filled in electro-
nically on the tablet PC in deidentified form. Medication
reviews and SMC will be documented by each GP for each
patient by using a form on the tablet PC. The data will be
stored in a secure central server of the University Hospital
Heidelberg. Only project personnel will have access to
these data.
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GPs will print out or copy the medication lists they
have stored in their PCP for each patient at T0 and T1.
Additionally, GPs will ask patients to show the medica-
tion lists they have with them when the patients give
their informed consent (T0) and at T1, copy and deiden-
tify these lists and send them to the study team. If a pa-
tient does not have a medication list with him or her, a
blank form will be sent.
Ethics
This study was approved by the ethics committee in
Heidelberg. The study will be carried out in compliance
with the Declaration of Helsinki (2008 version, Seoul,
Korea) and local legal regulations. All participants will
be asked to provide their written informed consent prior
to participation in the study.
Discussion
In this study, we will evaluate a program designed to im-
prove the implementation of recommendations for patients
with polypharmacy in PCP settings. Enrolment in the “HzV
AOK Baden-Württemberg” care contract and participation
in QCs are inclusion criteria. The participants in this
study have therefore different prerequisites for information
exchange with other physicians compared to the majority
of practices in Germany. However, the impact of this new
and still developing care model should not be overesti-
mated. Although the relatively low number of QCs in-
cluded in this study is not representative, choosing these
preexisting organisational structures as settings in this study
could be beneficial regarding a wider implementation of
the program in the future. Although a performance bias
due to the open nature of the trial should be considered,
the pragmatic character of the trial implies high external
validity and its results are likely to be applicable to other
practices in real-life situations. If the implementation
program proves to be effective, it could be offered to an
established network of about 300 QCs in the region
of Baden-Württemberg, thereby contributing to better
implementation of important recommendations for mana-
ging patients with polypharmacy in PCPs.
Trial status
Our trial is currently in the planning phase with recruit-
ment of practices started.
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